{"id":"intravenous-etoposide-cisplatin","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"20-30","effect":"Nephrotoxicity"},{"rate":"10-20","effect":"Ototoxicity"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"1-5","effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoposide is a topoisomerase II inhibitor that stabilizes the enzyme-DNA complex, preventing DNA replication and transcription. Cisplatin is a platinum-based alkylating agent that forms covalent crosslinks with DNA, causing strand breaks and apoptosis. Together, this combination provides synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Etoposide and cisplatin work together as a chemotherapy combination: etoposide inhibits topoisomerase II to prevent DNA unwinding, while cisplatin creates DNA crosslinks, both leading to cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:49.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Germ cell tumors"},{"name":"Lymphomas"}]},"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06077500","phase":"PHASE1","title":"DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":45},{"nctId":"NCT06132113","phase":"PHASE1","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-01-22","conditions":"Neuroendocrine Neoplasms","enrollment":55},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT02964013","phase":"PHASE1","title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-12-13","conditions":"Neoplasms","enrollment":474},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT07155122","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Small-Cell Carcinoma of the Esophageal","enrollment":15},{"nctId":"NCT05796089","phase":"PHASE2","title":"Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2022-01-01","conditions":"Extensive-Stage Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT05312671","phase":"PHASE2","title":"Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-27","conditions":"Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT04774380","phase":"PHASE3","title":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-11","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT05384015","phase":"PHASE2","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2022-11-07","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":46},{"nctId":"NCT06869239","phase":"","title":"Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02-25","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":65},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT06480864","phase":"NA","title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-08-09","conditions":"Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT03850067","phase":"PHASE1","title":"A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-03-12","conditions":"Small Cell Lung Carcinoma","enrollment":90},{"nctId":"NCT06536868","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC","status":"RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2024-08-01","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":40},{"nctId":"NCT04622228","phase":"PHASE2","title":"Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-16","conditions":"Carcinoma, Small Cell Lung","enrollment":56},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06485544","phase":"PHASE2","title":"Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-07-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":104},{"nctId":"NCT04562337","phase":"PHASE2","title":"SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-10-01","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06477523","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-16","conditions":"SCLC, Extensive Stage","enrollment":57},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT05765825","phase":"PHASE2","title":"Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2023-03-07","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":61},{"nctId":"NCT06371482","phase":"PHASE2","title":"Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-06-01","conditions":"SCLC, Limited Stage","enrollment":58},{"nctId":"NCT06372626","phase":"PHASE1, PHASE2","title":"Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-05-30","conditions":"Neuroendocrine Carcinoma","enrollment":93},{"nctId":"NCT06441344","phase":"PHASE3","title":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hospital","startDate":"2024-07-01","conditions":"SCLC, Maintenance Treatment","enrollment":136},{"nctId":"NCT06217757","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-18","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer","enrollment":45},{"nctId":"NCT06375109","phase":"PHASE2","title":"PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-04-16","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":60},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT05092412","phase":"PHASE2","title":"Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC","status":"UNKNOWN","sponsor":"You Lu","startDate":"2022-03-02","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab","enrollment":30},{"nctId":"NCT06177925","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-12-10","conditions":"Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site","enrollment":62},{"nctId":"NCT02580994","phase":"PHASE2","title":"Pembrolizumab in Untreated Extensive SCLC","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-08","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":125},{"nctId":"NCT06102746","phase":"","title":"Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-10","conditions":"Gastric Neuroendocrine Carcinoma","enrollment":20},{"nctId":"NCT03568097","phase":"PHASE2","title":"Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2018-09-16","conditions":"Small Cell Lung Carcinoma","enrollment":55},{"nctId":"NCT05873790","phase":"","title":"Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2023-06-01","conditions":"Lung Cancer","enrollment":30},{"nctId":"NCT05668767","phase":"PHASE2","title":"Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-12","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":20},{"nctId":"NCT02937116","phase":"PHASE1","title":"First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-10-19","conditions":"Cancer, Solid Tumor","enrollment":233},{"nctId":"NCT05484583","phase":"PHASE2","title":"Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2022-08-01","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy","enrollment":58},{"nctId":"NCT05245994","phase":"PHASE2","title":"An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2021-08-21","conditions":"Lung Cancer, Small Cell Lung Cancer, Durvalumab","enrollment":60},{"nctId":"NCT05142865","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-01-14","conditions":"Advanced or Metastatic EP-NEC","enrollment":30},{"nctId":"NCT05076786","phase":"PHASE2","title":"Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-27","conditions":"Neuroendocrine Tumors, Neuroendocrine Carcinoma","enrollment":28},{"nctId":"NCT04982549","phase":"PHASE2","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-01-21","conditions":"Unresectable Stage III NSCLC","enrollment":35},{"nctId":"NCT01840579","phase":"PHASE1","title":"Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-26","conditions":"Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT03901378","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2019-10-02","conditions":"Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site","enrollment":""},{"nctId":"NCT03116971","phase":"PHASE1","title":"Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-05-25","conditions":"Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT00514540","phase":"PHASE2","title":"Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Prostate Cancer","enrollment":121},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1},{"nctId":"NCT01450761","phase":"PHASE3","title":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-13","conditions":"Small Cell Lung Carcinoma","enrollment":1351},{"nctId":"NCT02786719","phase":"NA","title":"High-Risk Neuroblastoma Chemotherapy Without G-CSF","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00537511","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide","status":"TERMINATED","sponsor":"Celgene","startDate":"2008-02-01","conditions":"Carcinoma, Small Cell","enrollment":22},{"nctId":"NCT04065308","phase":"PHASE2","title":"Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-01-14","conditions":"Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab","enrollment":33},{"nctId":"NCT01822496","phase":"PHASE2","title":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-04","conditions":"Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7","enrollment":59},{"nctId":"NCT00554463","phase":"PHASE2","title":"G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-01","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT00031590","phase":"PHASE2","title":"Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2001-04","conditions":"Brain Tumors, Central Nervous System Tumors, Medulloblastoma","enrollment":30},{"nctId":"NCT02243436","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2014-11-11","conditions":"CLASSICAL HODGKIN LYMPHOMA","enrollment":67},{"nctId":"NCT00924209","phase":"PHASE2","title":"A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"NSCLC, Stage IIIA (N2)","enrollment":7},{"nctId":"NCT01453205","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-02-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":187},{"nctId":"NCT00577512","phase":"PHASE2","title":"2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT00320359","phase":"PHASE3","title":"Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-08","conditions":"Lung Cancer, Small Cell","enrollment":700},{"nctId":"NCT02883543","phase":"PHASE3","title":"First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2016-06","conditions":"Non-small Cell Lung Cancer","enrollment":330},{"nctId":"NCT00686959","phase":"PHASE3","title":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":598},{"nctId":"NCT01745445","phase":"PHASE2","title":"Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-01","conditions":"Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00658580","phase":"PHASE3","title":"Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2000-04","conditions":"Small Cell Lung Carcinoma, Extensive Disease","enrollment":361},{"nctId":"NCT01947062","phase":"PHASE3","title":"Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Swami Rama Cancer Hospital and Research Institute","startDate":"2013-10","conditions":"Lung Cancer, Squamous Cell Carcinoma of the Lung, Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung","enrollment":60},{"nctId":"NCT01210131","phase":"NA","title":"Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)","status":"WITHDRAWN","sponsor":"Maastricht Radiation Oncology","startDate":"2013-07","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":""},{"nctId":"NCT00621361","phase":"PHASE1","title":"Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Lung Cancer","enrollment":62},{"nctId":"NCT00089453","phase":"PHASE1","title":"Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-09","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT00403403","phase":"PHASE2","title":"A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-03","conditions":"Small Cell Lung Cancer","enrollment":102},{"nctId":"NCT01211002","phase":"PHASE4","title":"Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2010-10","conditions":"Non-small Cell Lung Cancer","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous etoposide/cisplatin","genericName":"Intravenous etoposide/cisplatin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoposide and cisplatin work together as a chemotherapy combination: etoposide inhibits topoisomerase II to prevent DNA unwinding, while cisplatin creates DNA crosslinks, both leading to cancer cell death. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}